Company intelligence / Profile preview

Anhui Oupushifang Pharmaceutical Technology Co., Ltd.

Ownership: Private
Development stage: Phase 3

Overview

Oupushifang Pharmaceutical Technology is conducting a multi-center, randomized, double-blind clinical trial to evaluate the effectiveness and safety of two concentrations of low-dose atropine sulfate eye drops (0.01% and 0.02%) in delaying the progression of myopia in children aged 6–12 years. The study is ongoing and currently recruiting participants as of March 2025[1].

Therapeutic areas: Ophthalmology
Modalities: Small molecules (specifically, low-dose atropine sulfate eye drops)
Industry: Biotech

Drug pipeline

1 asset

atropine sulfate

Phase 3

Indications: Myopia

Partnerships

Seefunge Pharmaceutical Technology Co., Ltd.OVCTEK/Autek China Inc.

Beyond the preview

Go deeper on Anhui Oupushifang Pharmaceutical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anhui Oupushifang Pharmaceutical Technology Co., Ltd..

Explore the full profile